Q BioMed, Inc. is a biomedical acceleration and development company. The Company focuses on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. Q BioMed acquires assets across healthcare related products, companies and sectors. It has portfolio of five therapeutic products, including Strontium-89 and MetastronTM for metastatic bone cancer pain and three development stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder; Uttroside-B for liver cancer, and MAN 01 for glaucoma. Its MAN platform has therapeutics in development in various indications, including vascular and infectious diseases. It holds license for a generic drug, Strontium Chloride (SR89). SR89 is a radiopharmaceutical agent and indicated for the treatment of bone cancer. The infectious diseases that it can treat includes influenza, COVID-19, Ebola and others. The Company's subsidiaries include Q BioMed Cayman SEZC and QBMG Q BioMed Germany UG.
Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.